Cancer therapy-induced bone loss (CTIBL) is a form of secondary osteoporosis associated with systemic chemotherapy and hormonal ablation therapy. The monitoring and treatment of CTIBL is an important component of comprehensive cancer care, especially for patients with curable disease and long life expectancies. Whereas oral bisphosphonates remain the most commonly used therapeutic option for CT...

1 Fondazione IRCCS Policlinico “San Matteo”, Pavia, Italy; 2 Fondazione IRCCS Istituto Nazionale Tumori , Milano, Italy; 3 Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; 4 Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte, Messina, Italy; 5 A.S.L. AT, Asti, Italy; 6 CHU Brugmann, ULB, Brussels, Belgium; 7 Amgen Spa, Milan, Italy; 8 United BioS...

Approximately 10 million men and women in the U.S. have osteoporosis,1 a metabolic bone disease characterized by low bone density and deterioration of bone architecture that increase the risk of fractures.2 Osteoporosis-related fractures can increase pain, disability, nursing home placement, total health care costs, and mortality.3 The diagnosis of osteoporosis is primarily determined by measur...

8 Abstract 9 Background In the present study, we undertook an 10 equivalence analysis on the effectiveness of the main anti11 reabsorptive agents indicated for women with osteoporosis. 12 Methods Our methodology was a combination of meta13 analysis (both pair-wise meta-analysis and network meta14 analysis) and equivalence testing. The end-point was the 15 incidence on new vertebral fractures. T...

Disseminated carcinomatosis of the bone marrow (DCBM) is caused by cancer metastasis to the bone marrow and is often accompanied by disseminated intravascular coagulation (DIC), with rapid clinical progression. We herein report two cases receiving treatment with combined androgen blockade (CAB) and denosumab for prostate cancer with DCBM. The patient in case 1 was an 80-year-old man who was adm...

BACKGROUND Facioscapulohumeral muscular dystrophy (FSHD) is the 3(rd) most common form of muscular dystrophy. Effective treatments for any of the muscular dystrophies have yet to be realized. This report describes such a treatment. CASE REPORT A 66 year old female was diagnosed with osteoporosis. She had been diagnosed with FSHD muscular dystrophy a number of years previously by both genetic ...

Our study evaluated the effects of one year-treatment with Denosumab (DB) on bone mineral density (BMD), FRAX SCORE, metabolism (MM) parameters and safety in 32-kidney transplanted patients (KTxps).

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the source is credited. DOI 10.3109/17453674.2013.859423 Stress fractures of the femoral shaft or subtrochanteric region (atypical femoral fractures) are clearly associated with bisphosphonat...

BACKGROUND Giant cell tumor of bone (GCTB) is a rare primary bone tumor, characterized by osteoclast-like giant cells that express receptor activator of nuclear factor-kappa B (RANK), and stromal cells that express RANK ligand (RANKL), a key mediator of osteoclast activation. A RANKL-specific inhibitor, denosumab, was predicted to reduce osteolysis and control disease progression in patients wi...

OBJECTIVE To assess the bone health status of children with cerebral palsy and the therapeutic effect of denosumab in a subgroup of children with cerebral palsy and decreased bone mass. METHODS Children with cerebral palsy were evaluated according to their motor disability score (classification system gross motor functions III to V), bone density and bone turnover markers. Dual X-ray energy a...